Gene · 3980
NIH grants1,564
NIH grants whose papers are about the gene, through NIH's grant-paper links.
161 to 180 of 1,564
Download this page as JSON| Grant | Title | LIG3 papers | Newest fiscal year |
|---|---|---|---|
| R01CA214799 | Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant Cancers | 1 | 2025 |
| R01CA218255 | Structure and Mechanism of Chromatin-Bound PARP1 | 1 | 2025 |
| R01CA237263 | DNA replication stress in cancer | 1 | 2025 |
| R01CA244261 | Mechanistic characterization of the cell cycle-dependent DNA repair pathway- Resubmission | 1 | 2025 |
| R01CA247992 | Targeting ferroptosis in radioresistance in lung cancer: mechanisms and preclinical translation | 1 | 2025 |
| R01CA248027 | Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancer | 1 | 2025 |
| R01CA248526 | Mechanisms of replication fork protection and recovery | 1 | 2025 |
| R01CA251141 | New mouse model of cisplatin-induced AKI and development of prevention therapy | 1 | 2025 |
| R01CA260628 | Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women | 1 | 2025 |
| R01CA262227 | Regulation of DNA replication kinetics by BRCA2 after DNA damage | 1 | 2025 |
| R01CA262316 | Co-Regulation of Alternative Lengthening of Telomeres and Chromatin Dynamics in ATRX-DAXX deficient cancer cells | 1 | 2025 |
| R01CA266100 | Deciphering the function of the APE2 nuclease during repair by alternative end-joining and its role in HR-deficient cells | 1 | 2025 |
| R01CA266524 | POLQ- and CtIP-regulated telomere fusions and translocations are involved in early events in carcinogenesis | 1 | 2025 |
| R01CA269646 | Targeting ferroptosis in cancer therapy | 1 | 2025 |
| R01CA279840 | Okazaki fragment maturation: mutagenesis and cell survival | 1 | 2025 |
| R01CA282939 | Understanding and Targeting the R-Loop-Mediated DNA Damage Response at Telomeres | 1 | 2025 |
| R01DK128282 | Biochemical and cellular mechanisms linking actin mutations to visceral myopathy | 1 | 2025 |
| R01ES007331 | Mechanisms of Methylmercury Induced Neuronal Toxicity | 1 | 2025 |
| R01ES010563 | Mechanisms of Manganese Neurotoxicity | 1 | 2025 |
| R01ES026184 | The Role of Mono-ADP-Ribosylation by PARP14 in Radioresistance | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3980/grants?page=9